While CAR T cell therapy—a personalized form of cancer immunotherapy first successfully developed by Carl June, MD, and his team at Penn—has revolutionized treatment for many blood cancers ...

Universal’s Monster Mash Hits the Theme Parks While Disney has kept Chernabog mostly in the shadows (save for a few brief cameos and fan merch), Universal is going all-in on the monsters that ...

Abeona's pz-cel gene therapy shows the most durable wound healing in RDEB patients with no treatment related severe adverse events. There have been no instances of Squamous Cell Carcinoma.

Locke, MD, provides insight on the design of the ALPHA and ALPHA2 trials, which are investigating the chimeric antigen receptor T-cell therapy (CAR T) cemacabtagene ansegedleucel (cema-cel ...

April 08, 2025--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced that a study titled "Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer ...

VIENNA, Va. - CEL-SCI Corporation (NYSE American: CVM), whose shares have declined nearly 85% over the past year according to InvestingPro data, today shared an update on its ongoing efforts to ...

This new Registration Study targets the population of previously untreated resectable stage 3 and 4 head and neck cancer patients who had no lymph node involvement and low PD-L1 tumor expression.

The FIRCE-1 trial for firi-cel in LBCL patients was discontinued due to insufficient therapeutic advantage and safety concerns. Firi-cel showed a 77% overall response rate, but only 18% of complete ...

We describe two patients in whom malignant monoclonal T-cell lymphoproliferation developed after administration of chimeric antigen receptor (CAR) T-cell therapy with ciltacabtagene autoleucel ...

The US Food and Drug Administration (FDA) has approved obecabtagene autoleucel, or obe-cel (AUTO1, Autolus Therapeutics) for the treatment of relapsed or refractory adult B-cell acute ...

RIO DE JANEIRO — A single infusion of the chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel, or cilta-cel (CARVYKTI, Janssen Biotech, Inc.), reduces the risk for death by ...